We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era.
- Authors
Song, Ga-Young; Yoon, Sang Eun; Kim, Seok Jin; Kim, Jin Seok; Koh, Youngil; Moon, Joon-Ho; Oh, Sung Yong; Lee, Ho Sup; Shin, Ho-Jin; Do, Young Rok; Lee, Won Sik; Kim, Dae sik; Park, Yong; Yhim, Ho-Young; Yang, Deok-Hwan
- Abstract
There are still controversies about the use of interim positron emission tomography/computed tomography (PET/CT) in indolent non-Hodgkin lymphoma due to the variable fluorodeoxyglucose (FDG) avidity. Therefore, this study aimed to evaluate the roles of interim PET/CT in marginal zone lymphoma (MZL), a representative indolent lymphoma. We analyzed the data of 146 MZL patients. All were treated with rituximab-containing immunochemotherapy. Interim PET/CT scan was performed after 2–3 cycles of therapy, and the response was assessed using the Deauville 5-point scales (5-PS) and a semi-quantitative assessment using the SUVmax reduction rate (ΔSUVmax). Progression-free survival (PFS) was well stratified according to a visual assessment of interim PET/CT using 5-PS (p < 0.001). Particularly, there was a significant difference in PFS between patients with interim score 1–2 and those with score 3. However, ΔSUVmax did not predict the survival outcome using 59.8% of the optimal cutoff value. In the multivariate analysis, failure to achievement of grade 1–2 in interim PET/CT was significantly associated with inferior PFS (HR, 2.154; 95% CI 1.071–4.332; p = 0.031). The interim PET/CT response based on the 5-PS is useful for predicting PFS of patients with MZL in the post-rituximab era.
- Subjects
FOSTER home care; COMPUTED tomography; IMMUNOTHERAPY; LYMPHOMAS; FLUORODEOXYGLUCOSE F18; RITUXIMAB
- Publication
Scientific Reports, 2020, Vol 10, Issue 1, p1
- ISSN
2045-2322
- Publication type
Article
- DOI
10.1038/s41598-020-68310-w